The facility covers 2,400 sq m and was built within one year following a €9m ($12.3m) investment. Rottendorf Pharma has highlighted the site’s melt extrusion, melt granulation and pellet technologies, which are intended to expand its service offering.
This is intended to “optimise its full service” by creating capacity for the formulation and process development, validation and manufacturing of small-scale, clinical and registration batches.
In particular completion of the new facility will allow the company to focus on process development for products with poorly soluble compounds.